Viatris(US:VTRS)2025-05-08 11:15Financial Performance Q1 2025 - Total Revenues were $3.3 billion, a decrease of 11% compared to Q1 2024[16, 74] - Adjusted EBITDA was $923 million, a decrease of 23% compared to Q1 2024[16, 74] - Adjusted EPS was $0.50, a decrease of 25% compared to Q1 2024[16, 74] - Free Cash Flow was $493 million, or $535 million excluding transaction costs[17] Impact of Indore Facility - The FDA issued a warning letter and import alert related to the oral finished dose manufacturing facility in Indore, India, leading to an estimated revenue impact of ~$140 million in Q1 2025[8, 94] - The estimated full-year 2025 revenue impact is ~$500 million, with an adjusted EBITDA impact of ~$385 million, including ~$100 million in penalties and supply disruptions[2, 94] - The estimated 2025 net sales impact by region is approximately $300 million in North America, $75 million in Europe, and $125 million in Emerging Markets[2] Financial Guidance 2025 - Total Revenues are projected to be between $13.5 billion and $14 billion[99] - Adjusted EBITDA is projected to be between $3.89 billion and $4.19 billion[99] - Adjusted EPS is projected to be between $2.16 and $2.30[99] - Free Cash Flow is projected to be between $1.8 billion and $2.2 billion[99] R&D Pipeline Update - Positive Phase 3 readouts were achieved for novel fast-acting meloxicam and XULANE LO[18] - A positive Phase 3 readout for EFFEXOR® for generalized anxiety disorder was achieved, and an sNDA was filed in Japan[18] - Selatogrel and cenerimod enrollment are on track[18] - The company is advancing 11 Phase 3 programs[22] Capital Allocation - The company returned >$450 million of capital to shareholders YTD, including >$300 million in share repurchases and ~$143 million in dividends paid[18, 111] - The company expects $500 million-$650 million in total share repurchases in 2025[2]